Back

Large number of real world evidence studies confirmed effectiveness and safety in treatment with Val/Aml and Val/Aml/HCT worldwide across various ethical groups, disease severities and co-morbidities

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 2 - Hypertension drug treatment Treatment of hypertension ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Kirstin Stricker

Novartis Pharma, Basel (Switzerland)

6 More presentations in this session

Presentation thumbnail
Combination of valsartan/amlodipine is more effective than bisoprolol/hydrochlorothiazide on reduction of blood pressure variability in patients with moderate or severe hypertension after control
Professor S. Shehata (El-Minya, EG)
Abstract Slides
Presentation thumbnail
Antihypertensive treatment effect on 24h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment
Professor S. Omboni (Solbiate Arno, IT)
Abstract Slides
Presentation thumbnail
Six-year trends in antihypertensive monotherapy: focus on blood pressure control and originals/generics ratio
Professor A. Konradi (Saint Petersburg, RU)
Abstract Slides
Presentation thumbnail
Which is the best choice? One year persistence of ramipril, ramipril/amlodipin free and fixed dose combination therapy in hypertension
Doctor G. Simonyi (Budapest, HU)
Abstract Slides
Presentation thumbnail
Effect of antihypertensive treatment with indapamide on bone metabolism in patients with arterial hypertension and osteoarthritis
Mrs K. Simbirtseva (Kyiv, UA)
Abstract Slides

Access the full session

Session thumbnail
Poster session 2 - Hypertension drug treatment

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources